Role of IGF-I in type 2 diabetes: A focus on the mouse model

Daniel Landau, Yael Segev

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Insulin resistance, the key mechanism in Type 2 diabetes mellitus (T2DM) is also associated wimth the deregulation of other glucose homeostasis pathways, such as the growth hormone (GH)-IGF-I system. In this review, we summarize the endocrine and renal GH-IGF axis changes in db/db mice, a model of T2DM, and compare it with the nonobese diabetic mouse model of T1DM. In the latter, elevated circulating GH levels (associated with kidney disease) could be ameliorated with the use of GH antagonists. Contrary to that, in the obese db/db mice, serum GH and IGF-I levels are decreased and tissue levels of IGF-binding protein 1 (Igfbp1) are increased. The latter hinted again for the known inverse correlation between insulin and Igfbp1 and was mediated by changes in the transcription factor phosphorylated forkhead box 01 in obese animals. In addition, the decrease in circulating IGF-I and GH levels causes a state of low free and active IGF-I, which may further impair tissue viability (including pancreatic β-cells). Thus, further GH inhibition to modulate complications in T2DM is not indicated, but the therapeutic role of IGF-1 in this disease remains to be determined.

Original languageEnglish
Pages (from-to)43-49
Number of pages7
JournalExpert Review of Endocrinology and Metabolism
Issue number1
StatePublished - 1 Jan 2008


  • Db/db mouse
  • Forkhead box O1
  • Growth hormone
  • IGF-binding protein 1
  • Nonobese diabetic mouse
  • Type 1 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Role of IGF-I in type 2 diabetes: A focus on the mouse model'. Together they form a unique fingerprint.

Cite this